Acute exercise increases the ventricular arrhythmia threshold via the intrinsic adenosine receptor system in conscious hypertensive rats

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 289, Issue 3 58-3, 2005, Pages

  Collins, Heidi L ^a   DiCarlo, Stephen E ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cardioprotective strategies; Coronary artery occlusion

Indexed keywords

ADENOSINE; ADENOSINE RECEPTOR; ADENOSINE RECEPTOR BLOCKING AGENT; ADENOSINE TRIPHOSPHATE; AMINOPHYLLINE; THEOPHYLLINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOVASCULAR RESPONSE; CONTROLLED STUDY; ELECTROCARDIOGRAPHY; EXERCISE; HEART INFARCTION; HEART PROTECTION; HEART RATE; HEART VENTRICLE ARRHYTHMIA; HYPERTENSION; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; RAT; STATISTICAL ANALYSIS; TREADMILL EXERCISE;

ACUTE DISEASE; ADAPTATION, PHYSIOLOGICAL; ANIMALS; BLOOD PRESSURE; CONSCIOUSNESS; CORONARY ARTERIOSCLEROSIS; EXERTION; HYPERTENSION; MYOCARDIAL ISCHEMIA; RATS; RECEPTORS, PURINERGIC P1; TACHYCARDIA, VENTRICULAR;

EID: 23944527333     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.00156.2005     Document Type: Article

References (51)

1. Babai L, Szigeti Z, Parratt JR, and Vegh A. Delayed cardioprotective effects of exercise in dogs are aminoguanidine sensitive: possible involvement of nitric oxide. Clin Sci (Lond) 102: 435-445, 2002.
2. Belardinelli L, Shryock JC, Song Y, Wang D, and Srinivas M. Ionic basis of the electrophysiological actions of adenosine on cardiomyocytes. FASEB J 9: 359-365, 1995.
3. Berne RM. Cardiac nucleotides in hypoxia: possible role in regulation of coronary blood flow. Am J Physiol 204: 317-322, 1963.
4. Collins HL, Loka AM, and DiCarlo SE. Daily exercise-induced cardioprotection is associated with changes in calcium regulatory proteins in hypertensive rats. Am J Physiol Heart Circ Physiol 288: H532-H540, 2005.
5. Crockett TR, Gray GA, Kane KA, and Wainwright CL. Sarafotoxin 6c (S6c) reduces infarct size and preserves mRNA for the ETB receptor in the ischemic/reperfused myocardium of anesthetized rats. J Cardiovasc Pharmacol 44: 148-154, 2004.
6. 2+ regulatory systems and ectonucleotidase activities in rat heart. J Appl Physiol 87: 152-160, 1999.
7. DiCarlo SE, Collins HL, Howard MG, Chen CY, Scislo TJ, and Patil RD. Postexertional hypotension: a brief review. Sports Med Training and Rehab 5: 17-27, 1994.
8. DiMarco JP. Adenosine and supraventricular tachycardia. Prog Clin Biol Res 230: 271-281, 1987.
9. DiMarco JP, Sellers TD, Berne RM, West GA, and Belardinelli L. Adenosine: electrophysiologic effects and therapeutic use for terminating paroxysmal supraventricular tachycardia. Circulation 68: 1254-1263, 1983.
10. DiMarco JP, Sellers TD, Lerman BB, Greenberg ML, Berne RM, and Belardinelli L. Diagnostic and therapeutic use of adenosine in patients with supraventricular tachyarrhythmias. J Am Coll Cardiol 6: 417-425, 1985.
11. Drake-Holland AJ, Laird JD, Noble MI, Spaan JA, and Vergroesen I. Oxygen and coronary vascular resistance during autoregulation and metabolic vasodilation in the dog. J Physiol (Lond) 348: 285-299, 1984.
12. Drury AN and Szent-Györgi A. The physiological activity of adenine compounds with especial reference to their action upon mammalian heart. J Physiol 68: 213-237, 1929.
13. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, Arensberg D, Baker A, Friedman L, Greene HL, and CAST Investigators. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 324: 781-788, 1991.
14. Ely SW, Knabb RM, Bacchus AN, Rubio R, and Berne RM. Measurements of coronary plasma and pericardial infusate adenosine concentrations during exercise in conscious dog: relationship to myocardial oxygen consumption and coronary blood flow. J Mol Cell Cardiol 15: 673-683, 1983.
15. Fishbein MC, Meerbaum S, Rit J, Lando U, Kanmatsuse K, Mercier JC, Corday E, and Ganz W. Early phase acute myocardial infarct size quantification: validation of the triphenyl tetrazolium chloride tissue enzyme staining technique. Am Heart J 101: 595-600, 1981.
16. Fredholm BB, Battig K, Holmen J, Nehlig A, and Zvartau EE. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev 51: 83-133, 1999.
17. I adenosine receptors. J Mol Cell Cardiol 30: 187-193, 1998.
18. Gifford RW. The role of multiple risk factors in cardiovascular morbidity and mortality. Cleve Clin J Med 60: 211-218, 1993.
19. Huikuri HV, Castellanos A, and Myerburg RJ. Sudden death due to cardiac arrhythmias. N Engl J Med 345: 1473-1482, 2001.
20. Janse MJ. A brief history of sudden cardiac death and its therapy. Pharmacol Ther 100: 89-99, 2003.
21. Joint National Committee on Detection. The fifth report of the Joint National Committee on Detection. Evaluation, and Treatment of high blood pressure (JNC V). Arch Intern Med 153: 154-183, 1993.
22. Jugdutt BI and Amy RW. Healing after myocardial infarction in the dog: changes in infarct hydroxyproline and topography. J Am Coll Cardiol 7: 91-102, 1986.
23. Krisna G and Paradise RR. Mechanisms of chronotropic effects of volatile inhalation anesthetics. Anesth Analg 56: 173-181, 1977.
24. Kulics JM, Collins HL, and DiCarlo SE. Postexercise hypotension is mediated by reductions in sympathetic nerve activity. Am J Physiol Heart Circ Physiol 276: H27-H32, 1999.
25. Lawson DM, Duke JL, Zammit TG, Collins HL, and DiCarlo SE. Recovery from carotid artery catheterization performed under various anesthetics in male, Sprague-Dawley rats. Contemp Top Lab Anim Sci 40: 18-22, 2001.
26. Mader TJ and Gibson P. Adenosine receptor antagonism in refractory asystolic cardiac arrest: results of a human pilot study. Resuscitation 35: 3-7, 1997.
27. McKenzie JE, Steffen RP, and Haddy FJ. Relationships between adenosine and coronary resistance in conscious exercising dogs. Am J Physiol Heart Circ Physiol 242: H24-H29, 1982.
28. Merin RG. Effect of anesthetics on the heart. Surg Clin North Am 55: 759-774, 1975.
29. Moser GH, Schrader J, and Deussen A. Turnover of adenosine in plasma of human and dog blood. Am J Physiol Cell Physiol 256: C799-C806, 1989.
30. Mubagwa K, Mullane K, and Flameng W. Role of adenosine in the heart and circulation. Cardiovasc Res 32: 797-813, 1996.
31. Mullane K and Bullough D. Harnessing an endogenous cardioprotective mechanism: cellular sources and sites of action of adenosine. J Mol Cell Cardiol 27: 1041-1054, 1995.
32. Nagelhout JJ. Adenosine: novel antiarrhythmic therapy for supraventricular tachycardia. AANA J 60: 287-292, 1992.
33. Olsson RA and Pearson JD. Cardiovascular purinoceptors. Physiol Rev 70: 761-845, 1990.
34. Ornato JP and Peberdy MA. The mystery of bradyasystole during cardiac arrest. Ann Emerg Med 27: 576-587, 1996.
35. Perouansky M, Shamir M, Hershkowitz E, and Donchin Y. Successful resuscitation using aminophylline in refractory cardiac arrest with asystole. Resuscitation 38: 39-41, 1998.
36. Pettinger WA, Tanaka K, Keeton K, Campbell WB, and Brooks SN. Renin release, an artifact of anesthesia and its implications in rats. Proc Soc Exp Biol Med 148: 625-630, 1975.
37. Reimer KA, Jennings RB, Cobb FR, Murdock RH, Greenfield JC Jr, Becker LC, Bulkley BH, Hutchins GM, Schwartz RP Jr, and Bailey KR. Animal models for protecting ischemic myocardium: results of the NHLBI Cooperative Study. Comparison of unconscious and conscious dog models. Circ Res 56: 651-665, 1985.
38. Richardt G, Waas W, Kranzhofer R, Mayer E, and Schomig A. Adenosine inhibits exocytotic release of endogenous noradrenaline in rat heart: a protective mechanism in early myocardial ischemia. Circ Res 61: 117-123, 1987.
39. Roden DM. Risks and benefits of antiarrhythmic therapy. N Engl J Med 331: 785-791, 1994.
40. Rongen GA, Brooks SC, Pollard MJ, Ando S, Dajani HR, Notarius CF, and Floras JS. Effect of adenosine on heart rate variability in humans. Clin Sci (Lond) 96: 597-604, 1999.
41. Rongen GA, Floras JS, Lenders JW, Thien T, and Smits P. Cardiovascular pharmacology of purines (editorial). Clin Sci (Colch) 92: 13-24, 1997.
42. Schreieck J and Richardt G. Endogenous adenosine reduces the occurrence of ischemia-induced ventricular fibrillation in rat heart. J Mol Cell Cardiol 31: 123-134, 1999.
43. Serafin WE. Drugs used in the treatment of asthma. In Goodman & Gilmans's The Pharmacological Basis of Therapeutics, edited by Hardman JG and Limbird LE. New York, McGraw-Hill, 1995, chapt 28, p. 673.
44. Sommerschild HT and Kirkeboen KA. Adenosine and cardioprotection during ischaemia and reperfusion-an overview. Acta Anaesthesiol Scand 44: 1038-1055, 2000.
45. Stark U, Brodmann M, Lueger A, and Stark G. Antiarrhythmic effects of adenosine on ischemia-induced ventricular fibrillation. J Crit Care 16: 8-16, 2001.
46. Stone HL. Control of the coronary circulation during exercise. Annu Rev Physiol 45: 213-227, 1983.
47. Taylor P. Agents acting at the neuromuscular junction and autonomic ganglia. In Goodman & Gilmans's The Pharmacological Basis of Therapeutics, edited by Hardman JG and Limbird LE. New York, McGraw-Hill, 1995, chapt 9, p. 177-197.
48. Tebbenjohanns J, Pfeiffer D, Schumacher B, Korte T, Jung W, and Luderitz B. Exogenous adenosine as an anti-arrhythmia agent. Z Kardiol 85, Suppl 6: 191-199, 1996.
49. Viskin S, Belhassen B, Roth A, Reicher M, Averbuch M, Sheps D, Shalabye E, and Laniado S. Aminophylline for bradyasystolic cardiac arrest refractory to atropine and epinephrine. Ann Intern Med 118: 279-281, 1993.
50. Vivaldi MT, Kloner RA, and Schoen FJ. Triphenyltetrazolium staining of irreversible ischemic injury following coronary artery occlusion in rats. Am J Pathol 121: 522-530, 1985.
51. Werns SW, Shea MJ, and Lucchesi BR. Free radicals in ischemic myocardial injury. J Free Radic Biol Med 1: 103-110, 1985.